Anavex Life Sciences Corp (AVXL)

[nidan7500]

AVXL has patent app w/related orgs.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220180360796%22.PGNR.&OS=DN/20180360796&RS=DN/20180360796

A quick review from the Roth concert makes it clear that the FDACNS trials process is a mess lookin for some way to get cleaned up. ERP systems and AI offer a possible save the AXX move fore FDA CNS trials processing. The price of poker is about to go up substantially. BP is so screwed.

https://erpbiomarkers.org/

About ERPs

Event-related potentials (ERPs) are changes in the electroencephalogram (EEG) caused by sensory and cognitive processes. In schizophrenia, ERP deficits are associated with cortical synaptic pathophysiology, such as NMDAr (N-methyl-D-aspartate receptor) hypofunction, which is related to cognitive impairment experienced by these patients. For example, mismatch negativity (MMN) is an ERP associated with auditory novelty detection. MMN is impaired and correlates with cognitive and global function in patients with schizophrenia. The ability to measure a biomarker like MMN may play a predictive role in schizophrenia drug development.

About the ERP Biomarker Qualification Consortium, LLC

The ERP Biomarker Qualification Consortium, LLC, a subsidiary of Neuronetrix Solutions, LLC (dba Cognision), is a pharmaceutical industry collaboration that was established to formally qualify normative event-related potential (ERP) biomarkers with the goal of advancing and streamlining the clinical development of new investigational therapies for people with schizophrenia. Founding principal members include Alkermes, Inc., Anavex Life Sciences Corp., Cadent Therapeutics, H. Lundbeck A/S, Merck (known as MSD outside the United States and Canada), Neuronetrix Solutions, LLC (dba Cognision), Sage Therapeutics, Inc., and Takeda Pharmaceutical Company Limited